{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:43Z","timestamp":1794273943056,"version":"4.9.0"},"reference-count":36,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,5,6]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The prevalence of hypertension, a major cardiovascular risk factor, is increased in patients with rheumatoid arthritis (RA) and may be driven by immune activation. The purpose of this study was to determine if ambulatory 24-hour blood pressure (BP) is elevated in RA vs control participants and whether it is associated with immune activation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cross-sectional study of 46 patients with RA and 23 control participants. Participants wore an ambulatory BP monitor that obtained diurnal BP every 15-30 minutes and nocturnal BP every 30 minutes. Inflammatory mediators in plasma were measured using an inflammation proteomics panel. Differences in BP measurements were assessed by Mann-Whitney<jats:italic>U<\/jats:italic>test, and association with inflammatory mediators was assessed by Spearman correlation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with RA and control participants had similar office BP, but median ambulatory systolic BP (SBP) measurements (24-hour [RA 121 mmHg vs control 116 mmHg;<jats:italic>P<\/jats:italic>= 0.01], diurnal [RA 128 mmHg vs control 120 mmHg;<jats:italic>P<\/jats:italic>= 0.003], and nocturnal [RA 112 mmHg vs control 103 mmHg;<jats:italic>P<\/jats:italic>= 0.002]) were higher in patients with RA. Patients with RA also had higher nocturnal diastolic BP (DBP; RA 63 mmHg vs control 57 mmHg;<jats:italic>P<\/jats:italic>= 0.02), but other DBP measurements were similar. Nocturnal BP dipping was less in patients with RA (12%) compared to control participants (16%;<jats:italic>P<\/jats:italic>= 0.02). In patients with RA, higher 24-hour and nocturnal SBPs and less nocturnal dipping were strongly correlated with a wide range of inflammatory mediators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite similar office measurements, 24-hour and nocturnal SBP measurements were higher in patients with RA than in control participants and were strongly associated with inflammation.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2024-0205","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:25:35Z","timestamp":1715775935000},"page":"870-876","source":"Crossref","is-referenced-by-count":10,"title":["Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis: Association With Immune Activation"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-3309","authenticated-orcid":false,"given":"Michelle J.","family":"Ormseth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Oeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024090105300596000_51.9.870.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21288"},{"key":"2024090105300596000_51.9.870.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"2024090105300596000_51.9.870.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117952"},{"key":"2024090105300596000_51.9.870.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006"},{"key":"2024090105300596000_51.9.870.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9811"},{"key":"2024090105300596000_51.9.870.6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1177\/0961203320951274","article-title":"Ambulatory blood pressure in patients with systemic lupus erythematosus: association with markers of immune activation","volume":"29","author":"Carranza-Leon","year":"2020","journal-title":"Lupus"},{"key":"2024090105300596000_51.9.870.7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41371-018-0047-0","article-title":"Association of nocturnal blood pressure patterns with inflammation and central and peripheral estimates of vascular health in rheumatoid arthritis","volume":"32","author":"Gkaliagkousi","year":"2018","journal-title":"J Hum Hypertens"},{"key":"2024090105300596000_51.9.870.8","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpv119"},{"key":"2024090105300596000_51.9.870.9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070657"},{"key":"2024090105300596000_51.9.870.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2024090105300596000_51.9.870.11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/VHRM.S33515","article-title":"Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?","volume":"9","author":"Mahabala","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"2024090105300596000_51.9.870.12","doi-asserted-by":"publisher","DOI":"10.1161\/hy1001.092640"},{"key":"2024090105300596000_51.9.870.13","first-page":"1112","article-title":"Masked hypertension: understanding its complexity","volume":"38","author":"Franklin","year":"2017","journal-title":"Eur Heart J"},{"key":"2024090105300596000_51.9.870.14","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(90)90005-M"},{"key":"2024090105300596000_51.9.870.15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.133900"},{"key":"2024090105300596000_51.9.870.16","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.68"},{"key":"2024090105300596000_51.9.870.17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.10971"},{"key":"2024090105300596000_51.9.870.18","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1093\/eurheartj\/ehz754","article-title":"Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial","volume":"41","author":"Hermida","year":"2020","journal-title":"Eur Heart J"},{"key":"2024090105300596000_51.9.870.19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/HYPERTENSIONAHA.121.16501","article-title":"Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension \u2013 con side of the argument","volume":"78","author":"Turgeon","year":"2021","journal-title":"Hypertension"},{"key":"2024090105300596000_51.9.870.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.567"},{"key":"2024090105300596000_51.9.870.21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2024090105300596000_51.9.870.22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1759720X17719850","article-title":"Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study","volume":"9","author":"Mangoni","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024090105300596000_51.9.870.23","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.80"},{"key":"2024090105300596000_51.9.870.24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08037051.2016.1183460","article-title":"Effect of tumor necrosis factor-alpha inhibitors on ambulatory 24-h blood pressure","volume":"26","author":"Grossman","year":"2017","journal-title":"Blood Press"},{"key":"2024090105300596000_51.9.870.25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001406"},{"key":"2024090105300596000_51.9.870.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704008114"},{"key":"2024090105300596000_51.9.870.27","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13061"},{"key":"2024090105300596000_51.9.870.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.897"},{"key":"2024090105300596000_51.9.870.29","doi-asserted-by":"publisher","DOI":"10.1159\/000512210"},{"key":"2024090105300596000_51.9.870.30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14712598.2023.2204186","article-title":"REcovery and SURvival of patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab trial: RESURRECT","volume":"23","author":"Kr","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2024090105300596000_51.9.870.31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14712598.2021.1905794","article-title":"A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of itolizumab in moderate to severe ARDS patients due to COVID-19","volume":"21","author":"Kumar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2024090105300596000_51.9.870.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.10388"},{"key":"2024090105300596000_51.9.870.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.04.049"},{"key":"2024090105300596000_51.9.870.34","first-page":"55","article-title":"Osteoprotegerin is associated with subclinical left ventricular systolic dysfunction in non-dipper hypertensive patients: a 2D speckle tracking echocardiographic study","volume":"29","author":"Alizade","year":"2024","journal-title":"Blood Press Monit"},{"key":"2024090105300596000_51.9.870.35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1042\/CS20210643","article-title":"Osteoprotegerin regulates vascular function through syndecan-1 and NADPH oxidase-derived reactive oxygen species","volume":"135","author":"Alves-Lopes","year":"2021","journal-title":"Clin Sci"},{"key":"2024090105300596000_51.9.870.36","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-019-13139-9","article-title":"A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension","volume":"10","author":"Arnold","year":"2019","journal-title":"Nat Commun"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T12:32:33Z","timestamp":1725193953000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.3899\/jrheum.2024-0205"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0205","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}